IAEA Human Health Series No. 8
Subject Classification: 0101-Nuclear medicine (including radiopharmaceuticals)
English STI/PUB/1416; (ISBN:978-92-0-108809-3); 140 pp.; 7 figures; € 42.00; Date Published: 2009
There is increased global interest in radiolabelled biologicals for clinical applications. Influenced by the search for the ‘biological bullet’, a variety of strategies have evolved for radiolabelling biological products with a view to human health application. This publication describes the challenges that the in vivo use of these products brings and provides essentials from in vitro to in vivo validation in human investigations. Additional attention is paid to safety and the effective use of radiolabelled biologicals in a busy clinical setting. The publication will be a useful resource for nuclear medicine physicians, radiologists, radiopharmacists, pharmacologists and other researchers engaged with radiolabelling biologicals for clinical applications.
More Information on reusing IAEA copyright material
Orders and requests for information may also be addressed to:
Marketing and Sales Unit International Atomic Energy Agency Vienna International Centre PO Box 100, A-1400 Vienna, Austria Tel.: +43 1 2600 22529 +43 1 2600 22530 Fax: +43 1 2600 29302 Email: [email protected]
INTERNATIONAL ATOMIC ENERGY AGENCY, Clinical Translation of Radiolabelled Monoclonal Antibodies and Peptides, IAEA Human Health Series No. 8, IAEA, Vienna (2009).
Download to:
EndNote BibTeX
Read more